Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours

NCT01861496 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Phase 1: Advanced or Refractory Solid Tumours
Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin Cancer

Interventions

DRUG: LiPlaCis

Sponsor

Allarity Therapeutics